First-line anti-EGFR agents (panitumumab or cetuximab) plus chemotherapy in patients with metastatic colorectal cancer: Onco-colon turkey study subgroup analysis

Işıkdoğan, A.Türk, H.Bilir, C.Sendur, M.Karabulut, B.Artaç, M.Cicin, I.Geredeli, C.Alacacıoğlu, A.Kefeli, U.Harputluoğlu, H.Bozkurt, O.Çubukcu, E.Tural, D.Sakin, A.Çil, T.Dane, F.Çevik, D.Arslan, C.Karadurmuş, N.Gümüş, M.Yalçın, S.2024-12-042024-12-042022-06-010923-7534https://doi.org/10.1016/j.annonc.2022.04.180https://www.sciencedirect.com/science/article/pii/S0923753422008705?via%3Dihubhttps://hdl.handle.net/11452/48838Bu çalışma, 19 Haziran-02 Temmuz, 2022 tarihlerinde Barcelona[İspanya]’da düzenlenen ESMO 24. World Congress on Gastrointestinal Cancer Kongresi‘nde bildiri olarak sunulmuştur.eninfo:eu-repo/semantics/openAccessScience & technologyLife sciences & biomedicineOncologyFirst-line anti-EGFR agents (panitumumab or cetuximab) plus chemotherapy in patients with metastatic colorectal cancer: Onco-colon turkey study subgroup analysisMeeting AbstractS281S2813310.1016/j.annonc.2022.04.1801569-8041